2010-01-25 16:09:07 -
Research and Markets ( www.researchandmarkets.com/research/da0324/type_1_diabetes : 
) has announced the addition of GlobalData's new report " Type 1 Diabetes - Drug Pipeline Analysis and Market Forecasts to 2016 : " to their offering.
GlobalData, the industry analysis specialist's new report " Type 1 Diabetes - Drug Pipeline Analysis and Market Forecasts to 2016 : " is an essential source of information and analysis on the global type 1 diabetes disorder market. The report identifies the key trends shaping and driving the market, and provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the
pipeline products within the global diabetes disorder sector.
The Type 1 Diabetes Therapeutics Market is Forecast to Show Moderate Growth until 2016
GlobalData has estimated the global type 1 diabetes therapeutics market to be valued at $2.7 billion in 2009.
Type 1 Diabetes Therapeutics Market, Global, Revenues, 2001-2009
It is expected to grow to $4.1 billion with a Compound Annual Growth Rate (CAGR) of 6.1% by 2016. This growth is primarily attributed to the increase in average cost of therapy of existing treatment option and increased rate of treatment seeking in type 1 diabetes patients. Novo Nordisk and Eli Lilly remain the market leaders within the global type 1 diabetes Therapeutics market. The type 1 diabetes market accounted for only 11% of the total diabetes market and for approximately 8% of the total population suffering from type 1 diabetes.
Increase in Average Cost of Therapy Will be the Key Driver of the Market, Followed by increased Treatment Seeking
The prevalence rate for type 1 diabetes globally was identified at 0.6% and this accounted to approximately 4.2 million people. Type 1 diabetes is an autoimmune condition and is generally found in young adults and children. The number of people with type 1 diabetes is estimated to increase at a slower rate of 1.2% between 2009 and 2016. The number of type 1 diabetes patients had increased with a higher rate of 1.5% during the period 2001-1009. Therefore the increase in average cost of therapy will be the key to growth in the market. The average cost of therapy is expected to increase at a CAGR (2009-2016) OF 4.5%. The increase in average cost of therapy is primarily driven by the higher cost of insulin analogs. The increase in awareness about type 1 diabetes due to awareness programs held in key countries will continue to improve the treatment seeking behavior. The increase in people who seek treatment can be converted to increase in prescription through effective diagnosis tests available in the market.
Scope.
- Annualized global type 1 diabetes market revenues data from 2000 to 2009, forecast forward for 7 years to 2016.
- Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future market competition in the global type 1 diabetes market. Key market players include Novo Nordsik, Eli Lilly, GlaxoSmithKline and Sanofi-aventis.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with type 1 diabetes.
Reasons to buy.
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global type 1 diabetes market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global type 1 diabetes market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global type 1 diabetes market landscape? - Identify, understand and capitalize.
Key Topics Covered:
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Type 1 Diabetes Therapeutics Market: Market Characterization
2.1 Overview
2.2 Type 1 Diabetes Market Size
2.3 Type 1 Diabetes Therapeutics Market Forecast and CAGR
2.4 Drivers and Barriers for the Type 1 Diabetes Therapeutics Market
2.4.1 Drivers for the Type 1 Diabetes Therapeutics Market
2.4.2 Restraints for the Type 1 Diabetes Therapeutics Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway 3 Type 1 Diabetes Therapeutics Market: Competitive
Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in the Type 1 Diabetes
Disease Market
3.3.1 Lantus (Insulin Glargine)
3.3.2 Humulin (Human Insulin)
3.3.3 Humalog (Insulin Lispro)
3.3.4 Novolog (Insulin Aspart)
3.3.5 Novolin (Human Insulin)
3.3.6 Apidra (Insulin Glulisine)
3.3.7 Levemir (Insulin Detemir)
3.4 Key Takeaway
4 Type 1 Diabetes Therapeutics Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytic Framework
4.3 Type 1 Diabetes Therapeutics - Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
4.4.1 rhGAD65 (Diamyd)
4.4.2 DiaPep277
4.4.3 Otelixizumab
4.4.4 Oral-lyn
4.5 Type 1 Diabetes Therapeutics Market - Clinical Pipeline by Mechanism of
Action
4.6 Type 1 Diabetes Pipeline - Pipeline by Clinical Phases of Development
4.6.1 Type 1 Diabetes Therapeutics - Filed and Approved Drugs
4.6.2 Type 1 Diabetes Therapeutics - Phase III Clinical Pipeline
4.6.3 Type 1 Diabetes Therapeutics - Phase II Clinical Pipeline
4.6.4 Type 1 Diabetes Therapeutics - Phase I Clinical Pipeline
4.6.5 Type 1 Diabetes Therapeutics - Phase I Clinical Pipeline
4.7 Key Takeaway
5 Type 1 Diabetes Market: Implications for Future Market Competition
6 Type Diabetes Therapeutics Market: Future Players in the Type 1 Diabetes
Therapeutics Market
6.1 Introduction
6.2 Novo Nordisk
6.2.1 Business Description
6.2.2 Metabolic Disorders Portfolio
6.2.3 Type 1 Diabetes Pipeline Portfolio
6.3 GlaxoSmithKline
6.3.1 Business Description
6.3.2 Metabolic Disorders Portfolio
6.3.3 Type 1 Diabetes Pipeline Portfolio
6.4 Eli Lilly
6.4.1 Business Description
6.4.2 Metabolic Disorders Portfolio
6.4.3 Type 1 Diabetes Pipeline Portfolio
6.5 Sanofi-aventis
6.5.1 Business Description
6.5.2 Metabolic Disorders Portfolio
6.5.3 Type 1 Diabetes Pipeline Portfolio
7 Type 1 Diabetes Therapeutics Market: Appendix
7.1 Definitions
7.2 Abbreviations
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary Research
7.3.5 Expert Panel Validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources
Companies Mentioned.
Novo Nordisk GlaxoSmithKline Eli Lilly Sanofi-aventis
For more information visit
www.researchandmarkets.com/research/da0324/type_1_diabetes :
Research and MarketsLaura Wood, Senior Manager
press@researchandmarkets.com : mailto:press@researchandmarkets.com U.S.
Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716
